Innovative Therapeutics SystImmune specializes in developing novel bispecific and trispecific antibody therapeutics targeting cancer micro-environments, particularly EGFR and HER3 pathways, providing opportunities to collaborate with pharmaceutical companies seeking cutting-edge immuno-oncology solutions.

Recent Product Launch The recent launch of iza-bren, a first-in-class ADC developed in partnership with Bristol Myers Squibb, demonstrates active product development and potential for strategic partnerships or licensing agreements in the oncology space.

Strong Industry Presence Participation and abstract presentations at global lung cancer conferences such as ELCC 2026 and WCLC 2025 position SystImmune as a recognized player in lung cancer therapeutics, offering opportunities for partnerships with research institutions and healthcare providers.

Growing Financials With an estimated revenue between 50 and 100 million dollars, SystImmune is a mid-stage biotech company with increasing market traction, making it a promising partner for investors and collaborators interested in expanding immuno-oncology pipelines.

Technology-Driven Approach Utilizing advanced platforms like Tableau, AngularJS, and Microsoft 365, SystImmune leverages technology to optimize drug development and data analysis, creating potential for partnerships with tech firms specializing in biotech data solutions or automation tools.